Magnetic nanoparticles detect amoxicillin allergy with 98% sensitivity in early tests

Researchers at the University of Malaga have created a novel technology utilizing magnetic nanoparticles to swiftly and accurately diagnose allergies to beta-lactam antibiotics, such as amoxicillin. The 30 nm nanoparticles, featuring an iron oxide core and silica shell, function as microscopic magnets equipped with numerous molecular receptors. When present in a patient's blood, the nanoparticles effectively capture IgE antibodies associated with the allergy, surpassing conventional methods in sensitivity.

The study, published in Materials Today Bio, involved researchers from the IBIMA BIONAD Platform, the Inflammatory Diseases Network (REI), and the Regional University Hospital of Malaga. The lead authors, Yolanda Vida and María I. Montañez, reported that the new system detected virtually all true cases of allergy while substantially reducing false negatives and false positives.

Professor of Medicine, María José Torres, highlighted that penicillin allergy is often overdiagnosed, leading to ineffective and potentially toxic alternative medications and contributing to the development of antibiotic resistance.

The researchers tested the technology using blood samples from 50 patients with confirmed amoxicillin allergy and 44 individuals who were tolerant to these antibiotics. Compared to ImmunoCAP, the most widely used commercial test, the new method demonstrated significantly higher sensitivity, achieving a 98% sensitivity rate for amoxicillin, whereas ImmunoCAP detected only around 17%.

The researchers emphasize the necessity for further large-scale studies and clinical validation before the technology can be widely adopted in hospitals.